Literature DB >> 33443248

Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.

Qingyu Zhao1, Yanan Gao1, Min Xiao2, Xuefei Huang3, Xuanjun Wu4.   

Abstract

For prevention of the coronavirus disease 2019 caused by the novel coronavirus SARS-CoV-2, an effective vaccine is critical. Herein, several potential peptide epitopes from the spike protein of SARS-CoV-2 have been synthesized and covalently linked with the cross-reactive material (CRM197). Immunization of mice with the resulting conjugates induced high titers of IgG antibodies against the spike protein. Importantly, the post-immune sera effectively neutralized SARS-CoV-2 pseudovirus, suggesting the epitopes identified are protective, and these conjugates are promising leads for anti-SARS-CoV-2 vaccine development.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33443248      PMCID: PMC8120452          DOI: 10.1039/d0cc08265a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  26 in total

1.  Development of Globo-H cancer vaccine.

Authors:  Samuel J Danishefsky; Youe-Kong Shue; Michael N Chang; Chi-Huey Wong
Journal:  Acc Chem Res       Date:  2015-02-10       Impact factor: 22.384

2.  Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.

Authors:  Xiaoxiao Qi; Bixia Ke; Qian Feng; Deying Yang; Qinghai Lian; Zibo Li; Linlin Lu; Changwen Ke; Zhongqiu Liu; Guochao Liao
Journal:  Chem Commun (Camb)       Date:  2020-07-02       Impact factor: 6.222

3.  Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

Authors:  T Gilewski; S Adluri; G Ragupathi; S Zhang; T J Yao; K Panageas; M Moynahan; A Houghton; L Norton; P O Livingston
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

4.  Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.

Authors:  Xuanjun Wu; Craig McKay; Christian Pett; Jin Yu; Manuel Schorlemer; Sherif Ramadan; Shuyao Lang; Sandra Behren; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2019-09-19       Impact factor: 5.100

5.  Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.

Authors:  Paul J Sabbatini; Govind Ragupathi; Chandra Hood; Carol A Aghajanian; Margrit Juretzka; Alexia Iasonos; Martee L Hensley; Maria K Spassova; Ouathek Ouerfelli; David R Spriggs; William P Tew; Jason Konner; Henrik Clausen; Nadeem Abu Rustum; Samuel J Dansihefsky; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

6.  Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.

Authors:  Natascha Stergiou; Markus Glaffig; Helmut Jonuleit; Edgar Schmitt; Horst Kunz
Journal:  ChemMedChem       Date:  2017-08-07       Impact factor: 3.466

7.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Authors:  Yushun Wan; Jian Shang; Rachel Graham; Ralph S Baric; Fang Li
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

8.  Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody.

Authors:  Zhe Lv; Yong-Qiang Deng; Qing Ye; Lei Cao; Chun-Yun Sun; Changfa Fan; Weijin Huang; Shihui Sun; Yao Sun; Ling Zhu; Qi Chen; Nan Wang; Jianhui Nie; Zhen Cui; Dandan Zhu; Neil Shaw; Xiao-Feng Li; Qianqian Li; Liangzhi Xie; Youchun Wang; Zihe Rao; Cheng-Feng Qin; Xiangxi Wang
Journal:  Science       Date:  2020-07-23       Impact factor: 47.728

9.  Structural basis of receptor recognition by SARS-CoV-2.

Authors:  Jian Shang; Gang Ye; Ke Shi; Yushun Wan; Chuming Luo; Hideki Aihara; Qibin Geng; Ashley Auerbach; Fang Li
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962

10.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

View more
  7 in total

1.  Structure Guided Design of Bacteriophage Qβ Mutants as Next Generation Carriers for Conjugate Vaccines.

Authors:  Suttipun Sungsuwan; Xuanjun Wu; Vincent Shaw; Herbert Kavunja; Hunter McFall-Boegeman; Zahra Rashidijahanabad; Zibin Tan; Shuyao Lang; Setare Tahmasebi Nick; Po-Han Lin; Zhaojun Yin; Sherif Ramadan; Xiangshu Jin; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2022-02-10       Impact factor: 4.634

2.  Developing Acid-Responsive Glyco-Nanoplatform Based Vaccines for Enhanced Cytotoxic T-lymphocyte Responses Against Cancer and SARS-CoV-2.

Authors:  Yanan Gao; Qingyu Zhao; Huiling Dong; Min Xiao; Xuefei Huang; Xuanjun Wu
Journal:  Adv Funct Mater       Date:  2021-07-17       Impact factor: 19.924

Review 3.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

4.  Active Humoral Response Reverts Tumorigenicity through Disruption of Key Signaling Pathway.

Authors:  Tracer Yong; Ko-Keng Chang; Yi-Sheng Wang; Che Ma
Journal:  Vaccines (Basel)       Date:  2022-01-21

5.  Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine.

Authors:  Shi-Hao Zhou; Yu-Ting Li; Ru-Yan Zhang; Yan-Ling Liu; Zi-Wei You; Miao-Miao Bian; Yu Wen; Jian Wang; Jing-Jing Du; Jun Guo
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

6.  Potent Neutralizing Antibodies Elicited by RBD-Fc-Based COVID-19 Vaccine Candidate Adjuvanted by the Th2-Skewing iNKT Cell Agonist.

Authors:  Xi-Feng Wang; Meng-Jia Zhang; Na He; Ya-Cong Wang; Cheng Yan; Xiang-Zhao Chen; Xiao-Fei Gao; Jun Guo; Rui Luo; Zheng Liu
Journal:  J Med Chem       Date:  2021-07-19       Impact factor: 7.446

7.  Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants.

Authors:  Bhaswati Chatterjee; Suman S Thakur
Journal:  Expert Rev Vaccines       Date:  2022-01-11       Impact factor: 5.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.